Bright Minds Biosciences Inc. (NASDAQ:DRUG – Get Rating) was the recipient of a significant decrease in short interest during the month of June. As of June 30th, there was short interest totalling 21,000 shares, a decrease of 56.3% from the June 15th total of 48,100 shares. Currently, 0.3% of the company's stock are short sold. Based on an average daily trading volume, of 54,500 shares, the days-to-cover ratio is presently 0.4 days.
Institutional Investors Weigh In On Bright Minds Biosciences
Several hedge funds have recently made changes to their positions in the business. AdvisorShares Investments LLC raised its holdings in Bright Minds Biosciences by 115.5% during the first quarter. AdvisorShares Investments LLC now owns 206,716 shares of the company's stock worth $314,000 after purchasing an additional 110,774 shares in the last quarter. Jane Street Group LLC purchased a new position in Bright Minds Biosciences during the first quarter worth about $37,000. Finally, Checchi Capital Advisers LLC purchased a new position in Bright Minds Biosciences during the fourth quarter worth about $45,000. Institutional investors and hedge funds own 7.70% of the company's stock.
Get Bright Minds Biosciences alerts:Bright Minds Biosciences Stock Performance
NASDAQ DRUG traded up $0.01 during trading hours on Friday, hitting $0.85. The company had a trading volume of 10,647 shares, compared to its average volume of 26,129. Bright Minds Biosciences has a 1-year low of $0.75 and a 1-year high of $8.95. The business has a 50 day moving average of $0.93 and a 200-day moving average of $1.62.
Bright Minds Biosciences (NASDAQ:DRUG – Get Rating) last released its quarterly earnings data on Monday, May 16th. The company reported ($0.30) earnings per share (EPS) for the quarter.Bright Minds Biosciences Company Profile
(Get Rating)
Bright Minds Biosciences Inc, a pre-clinical biosciences company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. Its portfolio of selective 5-HT receptor agonists comprises 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry.
Featured Articles
- Get a free copy of the StockNews.com research report on Bright Minds Biosciences (DRUG)
- MarketBeat: Week in Review 7/11 – 7/15
- Is Coupang's Stock On The Verge Of A Turnaround?
- Should You Have These Two Banks In Your Portfolio?
- Verint Systems Stock is a Customer Engagement Play
- Why Shopify Stock Split...And is as Shoppable as Ever
Receive News & Ratings for Bright Minds Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bright Minds Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.